ArticleHaematologica2016

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Aurore Perrot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.